Can pharmacies compound BPC-157 now? The HHS peptide policy explained

• Yes, for six peptides. Since October 28, 2026, an HHS interim policy says HHS will not go after state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157, epitalon, KPV, MOTS-c, Semax or TB-500.
• You need a prescription. Every product is made for a named patient.
• Each peptide has fixed routes, and every product holds one peptide only. No blends.
• It is not FDA approval. It is a draft, non-binding policy that lasts until FDA rules on each peptide, and HHS can pull it on a safety signal.

• BPC-157 acetate: subcutaneous or intramuscular injection, oral, or topical.
• TB-500 acetate (Ac-LKKTETQ, the thymosin beta-4 fragment): subcutaneous or intramuscular injection.
• Epitalon acetate: subcutaneous or intramuscular injection, dispensed in intermittent courses.
• Semax free base: intranasal only.
• KPV acetate: topical or oral.
• MOTS-c acetate: subcutaneous or intramuscular injection.

HHS pins each peptide to one exact identity in its Appendix B: amino acid sequence, molecular formula and molecular weight. Five are the acetate salt and Semax is the free base. Other forms do not match, so BPC-157 arginate or N-acetyl Semax amidate sit outside the policy, and so does any route not on the list, such as injectable KPV or nasal epitalon.

A prescription written for you by a licensed prescriber, and a state-licensed pharmacy, a federal facility or a licensed physician to compound it. That is the whole access route. Research-use-only vials are not part of it, and HHS says that is the point: the policy is meant to discourage the widespread use of research-use-only peptides from foreign manufacturers by giving patients a more controlled option.

• Use one of the six, with the exact identity and route HHS lists.
• Buy the raw ingredient (API) from an FDA-registered manufacturer that follows CGMP, with a certificate of analysis showing identity, purity, potency and tests for contaminants such as endotoxins, heavy metals and microbes. The original maker's address goes on the certificate.
• Put one active ingredient in each product. No blends.
• Label it "This is a compounded drug product. Not for resale." and tell the patient how to report problems.
• Report serious adverse events and quality problems to FDA MedWatch and to the states where the product is made and sent.
• For oral products, keep documentation that the specific formulation is absorbed in people.
• Use no delivery device beyond an FDA 510(k)-cleared syringe. Pens and autoinjectors are out.
• Follow the rest of the law, including clean compounding conditions and a patient-specific prescription.

• It does not approve anything. In HHS's own words, compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are sold.
• It does not bind anyone. The notice says it creates no rights and is not binding on HHS or the public, and HHS can revisit it if a safety signal or quality problem appears.
• It does not cover blends: BPC-157 + TB-500, GLOW, KLOW and Selank + Semax stay outside it.
• It does not cover other peptides. CJC-1295, ipamorelin, GHK-Cu and retatrutide are not on the list.
• It does not replace the states. The policy covers state-licensed pharmacies, and reports go to the states involved.

• September 2023: FDA placed the six in Category 2, its list of substances that may pose significant safety risks.
• April 22, 2026: they came off Category 2 after the nominations were withdrawn. That alone did not make them compoundable.
• July 23 to 24, 2026: FDA's Pharmacy Compounding Advisory Committee voted in favor of all six, against the advice of FDA's drug center.
• October 28, 2026: HHS posted the policy.
• October 30, 2026: the Federal Register notice ran (FR Doc. 2026-22192), opening a two-week comment window on regulations.gov, docket HHS-OASH-2026-0496.
• After that: the policy holds for each peptide until FDA addresses it in a final 503A rule, which could list it or not.

FDA's drug center (CDER) recommended against listing each of the six, and HHS's own appendix says so peptide by peptide. HHS's reply is that new lot-level certificates of analysis, documented use and the policy's conditions answer CDER's concerns. The Associated Press reported that FDA scientific staffers had little input on the decision and opposed the changes, citing six people familiar with it. So the policy exists over the objections of the agency's scientists, and the comment window is the public's turn.